Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

Rituximab leads to longer remission and fewer side effects than cyclophosphamide.

Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair cells.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.

CAR-T therapy offers hope for children with hard-to-treat blood cancers.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Chemotherapy causes hair loss starting soon after treatment begins and recovers about 3 months after ending, while tamoxifen does not significantly affect hair growth.

Alpha-difluoromethylornithine prevents cancer in mice but causes hair loss.

Inhibiting TYK2 can restore hair growth in alopecia areata.

A new triple drug system using nanoparticles effectively targets breast tumors in 3D models.

Tacrolimus can cause hair loss in kidney transplant patients.

More research is needed to confirm initial findings on hair loss patterns from chemotherapy.

Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.

Trichoblastomas in rabbits are linked to uncontrolled embryonic hair growth and have distinct histological features.

Targeted cancer therapies can cause skin side effects, but activating SOS in the skin may help reduce them.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Licorice component glycyrrhizic acid may reduce skin side effects from cancer treatment.

Chemotherapy for breast cancer often causes significant and lasting hair loss.

Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.

Leflunomide successfully treated a rare skin condition in a liver transplant patient.